PLRX - Pliant Therapeutics Inc logo

Pliant Therapeutics Inc

PLRX

Pliant Therapeutics develops integrin-based therapies targeting solid tumors and fibrotic diseases. Its lead product, PLN-101095, is an oral dual inhibitor in clinical trials, supported by a proprietary library of over 15,000 integrin-binding molecules.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$51today

Score Overview

1 Year
Score—
Net Growth38.20%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.1
Net Growth-415.38%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
All Time
Score
Net Growth-132.20%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend17%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Pliant Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PLRX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 0.89—
1 Year2025-10-21
$ 1.87-52.63%
5 Years2021-10-21
$ 17.28-94.87%
All Time2020-06-03
$ 21.30-95.84%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 92M$ 158M
2025$ 0.00-$ 149M$ 190M
2024$ 0.00-$ 210M$ 355M
2023$ 1M-$ 161M$ 494M
2022$ 9M-$ 123M$ 331M
2021$ 7M-$ 17M$ 200M
IPO2020$ 41M-$ 39M$ 276M
PLRX - Pliant Therapeutics Inc logo

Pliant Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 41M to $ 0.00 and net income went from -$ 39M to -$ 149M. Revenue increased in 1 of those 5 years; net income in 2.

Pliant Therapeutics Inc currently holds a 5-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.

Membership

Explore PLRX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies